quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:11:16·38d
SECFiling
Coya Therapeutics Inc. logo

SEC Form 10-K filed by Coya Therapeutics Inc.

COYA· Coya Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • COYA
    Coya Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 9UpdateLake Street$16.00
  • Dec 4UpdateD. Boral Capital$15.00

Related

  • INSIDER14d
    SEC Form 4 filed by Pavao Mark H
  • INSIDER14d
    SEC Form 3 filed by new insider Pavao Mark H
  • PR14d
    Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
  • SEC21d
    SEC Form 8-K filed by Coya Therapeutics Inc.
  • PR30d
    ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
  • SEC32d
    SEC Form EFFECT filed by Coya Therapeutics Inc.
  • SEC34d
    SEC Form 424B3 filed by Coya Therapeutics Inc.
  • PR36d
    Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022